June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Development of triamcionolone acetonide based lipid nanocapsules as platforms for ocular drug delivery
Author Affiliations & Notes
  • María Lina Formica
    Faculty of Chemical Sciences - Pharmacy, University of Córdoba, Córdoba, Argentina
    Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA) - CONICET, Córdoba, Argentina
  • Gabriela Veronica Ullio Gamboa
    Faculty of Chemical Sciences - Pharmacy, University of Córdoba, Córdoba, Argentina
    Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA) - CONICET, Córdoba, Argentina
  • Jean Pierre Benoit
    Laboratoire INSERM U1066-IBS-CHU Angers (France), Angers, France
  • Daniel Alberto Allemandi
    Faculty of Chemical Sciences - Pharmacy, University of Córdoba, Córdoba, Argentina
    Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA) - CONICET, Córdoba, Argentina
  • Jose D Luna Pinto
    Ctr Privado de Ojos Romagosa-Fndtn VER, Córdoba, Argentina
  • Santiago Daniel Palma
    Faculty of Chemical Sciences - Pharmacy, University of Córdoba, Córdoba, Argentina
    Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA) - CONICET, Córdoba, Argentina
  • Footnotes
    Commercial Relationships María Formica, None; Gabriela Ullio Gamboa, None; Jean Benoit, None; Daniel Allemandi, None; Jose Luna Pinto, None; Santiago Palma, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4152. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      María Lina Formica, Gabriela Veronica Ullio Gamboa, Jean Pierre Benoit, Daniel Alberto Allemandi, Jose D Luna Pinto, Santiago Daniel Palma; Development of triamcionolone acetonide based lipid nanocapsules as platforms for ocular drug delivery. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4152.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Triamcinolone acetonide (TAA) is considered a first-line drug by itself or as a combined treatment of several intraocular diseases such as macular edema, retinal vein thrombosis, uveitis and age-related macular degeneration. The development of TAA dosage forms is limited due to its poor solubility in water and physiologically acceptable solvents. Lipid nanocapsules (LNCs) are biocompatible systems that allow loading both hydrophobic and hydrophilic drugs. LNCs present a versatile composition and application suitable for different routes of administration. The aim of this work was to develop and characterize a novel lipid LNCs formulation containing TAA as drug delivery system.

 
Methods
 

LNCs were prepared in triplicate using an optimized phase inversion-based method described by Heurtault et al., 2002. Due to the poor solubility of TAA in the oily phase of the original formulation, two co-surfactants (captex® 500p -Glyceryl triacetate and oleic acid) in three proportions (20, 30 and 50%) were tested. The average particle size (APS), polydispersity index (PI), zeta potential (ZP) and entrapment efficacy (EE) were measured.

 
Results
 

Acceptable results were obtained with a 20% of both co-surfactants. LNCs with captex® 500p leads to about (40±1) nm size nanoparticles with a narrow size distribution (PI less than 0.2), a negative ZP (-1.2±0.7) mV and EE (85.8±0.8) % while LNCs with oleic acid showed an APS of (35.9± 0.6) nm and a PI below 0.1 with a negative ZP (-3.6±0.6) mV and EE (87±2) %. Moreover, both systems were stable for two months.

 
Conclusions
 

LNCs allow encapsulation of TAA and their properties remain constant over long periods of time. Thus, LNCs are promising systems than may be a potential strategy to improve efficacy and decrease side effects of this drug so used in the treatment of intraocular diseases.  

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×